** Shares of Australian drugmaker Mayne Pharma MYX.AX fall as much as 7.7% to A$4.11, their lowest since Aug. 23
** Co provides no update on potential buyout interest, at its annual general meeting
** MYX earlier in the month said Jefferies to assist co in terms of looking for a possible bidder
** Stock posts its biggest intraday pct fall since Nov. 13
** Co says total revenue for the July-Oct period came in at A$132.5 mln ($86.32 mln), lower than the A$137 mln reported in the previous corresponding period
** Two analysts covering the stock rate it "buy" or higher, their median PT is A$2.0 – LSEG data
** Stock had fallen 32.7% this year, as of last close
($1 = 1.5349 Australian dollars)
(Reporting by Nichiket Sunil)
((Nichiket.Sunil@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.